Exchange: NASDAQ·Updated 07:58 PM EDT

About CTY

About

City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A

Frequently Asked Questions

What is Market Cap of City Therapeutics Inc.?
What is the 52-week high for City Therapeutics Inc.?
What is the 52-week low for City Therapeutics Inc.?
What is City Therapeutics Inc. stock price today?
What was City Therapeutics Inc. stock price yesterday?
What is the 50-day moving average of City Therapeutics Inc.?

Advertisement|Remove ads.